Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Medicine, Duke University, Durham, NC, USA.
Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
Immunity. 2018 Dec 18;49(6):1162-1174.e8. doi: 10.1016/j.immuni.2018.10.015. Epub 2018 Dec 11.
Elicitation of VRC01-class broadly neutralizing antibodies (bnAbs) is an appealing approach for a preventative HIV-1 vaccine. Despite extensive investigations, strategies to induce VRC01-class bnAbs and overcome the barrier posed by the envelope N276 glycan have not been successful. Here, we inferred a high-probability unmutated common ancestor (UCA) of the VRC01 lineage and reconstructed the stages of lineage maturation. Env immunogens designed on reverted VRC01-class bnAbs bound to VRC01 UCA with affinity sufficient to activate naive B cells. Early mutations defined maturation pathways toward limited or broad neutralization, suggesting that focusing the immune response is likely required to steer B cell maturation toward the development of neutralization breadth. Finally, VRC01 lineage bnAbs with long CDR H3s overcame the HIV-1 N276 glycan barrier without shortening their CDR L1, revealing a solution for broad neutralization in which the heavy chain, not CDR L1, is the determinant to accommodate the N276 glycan.
诱导 VRC01 类广谱中和抗体 (bnAbs) 是预防 HIV-1 疫苗的一种有吸引力的方法。尽管进行了广泛的研究,但诱导 VRC01 类 bnAbs 和克服包膜 N276 聚糖带来的障碍的策略尚未成功。在这里,我们推断了 VRC01 谱系的高概率未突变共同祖先 (UCA),并重建了谱系成熟的阶段。基于回复的 VRC01 类 bnAbs 设计的 Env 免疫原与 VRC01 UCA 具有足够的亲和力结合,足以激活幼稚 B 细胞。早期突变定义了向有限或广泛中和的成熟途径,表明可能需要集中免疫反应来引导 B 细胞成熟,以发展中和广度。最后,具有长 CDR H3 的 VRC01 谱系 bnAbs 克服了 HIV-1 N276 聚糖障碍,而没有缩短其 CDR L1,揭示了广泛中和的解决方案,其中重链而不是 CDR L1 是容纳 N276 聚糖的决定因素。
Nat Rev Immunol. 2025-7-24
Commun Biol. 2025-2-13
bioRxiv. 2024-12-4
Nat Commun. 2023-8-28
Cell Host Microbe. 2018-5-31
Sci Transl Med. 2017-3-15